Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors
Go back to Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors| (AMEX: IVBIY) | Delayed: 19.48 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $19.48 | 52 Week High | $ | |||
| Open | $19.48 | 52 Week Low | $ | |||
| Day High | $19.48 | P/E | N/A | |||
| Day Low | $19.48 | EPS | $ | |||
| Volume | 8,564 | |||||
